5 results
Primary objective:To demonstrate the efficacy of Rifaximin -EIR 400 mg Tablet (800mg /BID, total daily dose 1600 mg) versus placebo in the prevention of endoscopic Crohn*s disease recurrence following ileocolonic resection
To evaluate the safety and activity of BB3 compared to placebo in improving renal function in the immediate post-transplant period in patientswho have received a DCD kidney transplantation.
Primary Objective: Assessment of a group difference in clinically important improvement in functional outcome of at least 10 points as measured by the DASH questionnaireSecondary Objective(s): 1. To determine if there is a group difference in…
The objective of these studies is to identify the primary mechanisms of GC-induced dysmetabolic effects in humans and to find biomarkers that reflect these side effects of GC treatment and which can be followed during therapy and in future clinical…
To evaluate the safety and activity of BB3 compared to placebo in improving renal function in the immediate post-transplant period in patients who have received a DCD kidney transplantation.